Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
CONCLUSION: Cilta-cel efficacy and safety were comparable between CARTITUDE-1 patients with and without prior alloSCT. Additional studies are needed to fully elucidate the suitability of CAR-T cell therapy in the post-alloSCT setting.PMID:37716872 | DOI:10.1016/j.clml.2023.08.012
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Myo Htut Binod Dhakal Adam D Cohen Thomas Martin Jesus G Berdeja Saad Z Usmani Mounzer Agha Carolyn C Jackson Deepu Madduri William Deraedt Enrique Zudaire Tzu-Min Yeh Xiaoying Xu Lida Pacaud Muhammad Akram Sundar Jagannath Source Type: research
More News: Brain | Cancer & Oncology | Liver | Liver Transplant | Lung Transplant | Lymphoma | Myeloma | Neurology | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Urology & Nephrology